MedicalResearch.com Interview with:
Nathalie Scheers PhD
Chalmers University of Technology
Dept of Biology and Biological Engineering
Food and Nutrition Science
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Many different forms of iron supplements are used to treat iron deficiency symptoms or as phosphate binders in patients with renal disease. two of these iron supplements, the chelates ferric citrate and ferric EDTA have been observed to drive colon cancer in mice. In the newly published study in Oncotarget, we are reporting our work on how these iron compounds differ compared to the simple salt ferrous sulphate, which is another common iron supplement.
The main finding of this study was that ferric citrate and ferric EDTA promoted the cancer biomarker amphiregulin which in turn activated the MAP kinase ERK in gut epithelial cancer cells. There were no such effects in ferrous sulphate-treated cells. Continue reading